Vaccine Response Impaired Clinical Trial
Official title:
Hepatitis A Vaccination in Patients With Rheumatoid Arthritis Treated With TNF-inhibitors and/or Methotrexate
Hepatitis A vaccine is the most frequently used traveler's vaccine, yet data on its ability
to induce protective immunity in immunosuppressed travelers are scarce. The investigators
assess the hepatitis A virus (HAV) antibody response in patients with rheumatoid arthritis
(RA) treated with Tumor Necrosis Factor (TNF) - inhibitors and/or methotrexate (Mtx).
In a previous study, 2 doses were not considered effective and there is therefore need for a
study with an additional dose
Methods: Parameters registered at baseline were: age, sex, duration of disease, medications, activity of disease (Visual Analogue Scale), Health Assessment Questionnaire Disability Index, Disease Activity Score, Acute phase reactant and total immunoglobulin G in plasma). Hepatitis A vaccine (Epaxal or Havrix) were given at 0 and 6 months. Hepatitis A virus (HAV) antibodies is measured before vaccination and at month 1, 6 (before dose 2), 7 and 12 with quantitative HAV IgG, using the HAVAb-IgG Architect System, and by the HAVAB 2.0 assay on the AxSYM machine from Abbott. The level of protective immunity to HAV is defined as HAV IgG > 10mIU/mL. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05060991 -
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
|
Phase 4 | |
| Completed |
NCT03855176 -
Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients
|
Phase 4 | |
| Not yet recruiting |
NCT05923970 -
Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
|
||
| Recruiting |
NCT05019248 -
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
|
||
| Completed |
NCT03467074 -
Role of Interferon-λ and Vaccine Response
|
||
| Completed |
NCT05124509 -
Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant
|
||
| Completed |
NCT05791851 -
Heplisav-B Revaccination for Hepatitis B Vaccine Nonresponders
|
||
| Completed |
NCT05030974 -
RECOVAC Repeated Vaccination Study
|
Phase 4 | |
| Completed |
NCT03930017 -
Pregnancy, Arsenic and Immune Response
|
||
| Completed |
NCT05116748 -
COVID19 Vaccine in SOT Adult Recipients
|
||
| Recruiting |
NCT06148025 -
Antibiotics and Vaccine Immune Responses Study
|
Phase 4 | |
| Completed |
NCT03368495 -
Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines
|
Phase 4 | |
| Completed |
NCT04059991 -
Antibodies in Repeated Influenza Vaccination (ARIVA) Study
|
||
| Completed |
NCT04912661 -
Iron and Vaccine Response
|
N/A | |
| Completed |
NCT04915820 -
Iron and COVID-19 Vaccine Response
|
N/A | |
| Completed |
NCT04885907 -
Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients
|
Phase 4 | |
| Completed |
NCT03588013 -
Study of Environmental Enteropathy and Malnutrition in Pakistan
|
N/A | |
| Completed |
NCT04936997 -
Immune Response to the COVID-19 Vaccine
|
Early Phase 1 | |
| Completed |
NCT03996538 -
Vaccination Efficacy With Metformin in Older Adults
|
Phase 1 | |
| Completed |
NCT02453113 -
Immune-Related Trafficking and Signaling in Human Skin Associated With Low-Power, Infrared Laser Treatment
|
N/A |